Luxturna

Luxturna is a gene therapy designed to treat a rare inherited form of vision loss caused by mutations in the RPE65 gene. It works by delivering a functioning copy of this gene directly into retinal cells, helping them produce the proteins necessary for healthy vision. Administered through a one-time surgical procedure, Luxturna can improve or stabilize vision in people affected by this specific genetic condition. It is currently the only FDA-approved treatment for this form of inherited retinal dystrophy, offering hope for improved quality of life for affected individuals.